Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$8.22 USD
+0.07 (0.86%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $8.19 -0.03 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Aligos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 16 | 14 | 4 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 16 | 14 | 4 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 104 | 111 | 133 | 98 | 54 |
Income After Depreciation & Amortization | -88 | -98 | -128 | -98 | -54 |
Non-Operating Income | 1 | 2 | 0 | -11 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -87 | -96 | -128 | -108 | -52 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -88 | -96 | -128 | -109 | -52 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -88 | -96 | -128 | -109 | -52 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -85 | -94 | -124 | -94 | -53 |
Depreciation & Amortization (Cash Flow) | 3 | 4 | 4 | 4 | 1 |
Income After Depreciation & Amortization | -88 | -98 | -128 | -98 | -54 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.57 | 1.71 | 1.59 | 0.40 | NA |
Diluted EPS Before Non-Recurring Items | -34.00 | -56.25 | -80.50 | -271.75 | NA |
Diluted Net EPS (GAAP) | -34.00 | -56.25 | -80.50 | -271.75 | -651.00 |
Fiscal Year end for Aligos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.06 | 0.99 | 2.68 | 3.24 | 6.89 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.06 | 0.99 | 2.68 | 3.24 | 6.89 |
SG&A, R&D, and Dept/Amort Expenses | 27.48 | 23.04 | 28.68 | 22.31 | 26.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | -26.42 | -22.05 | -26.00 | -19.07 | -19.14 |
Non-Operating Income | 31.66 | -12.79 | -1.93 | 1.06 | 1.11 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 5.25 | -34.84 | -27.92 | -18.01 | -18.03 |
Income Taxes | 0.19 | 0.02 | -0.03 | 0.03 | 0.76 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 5.06 | -34.86 | -27.89 | -18.04 | -18.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 5.06 | -34.86 | -27.89 | -18.04 | -18.79 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 6.27 | 6.25 | 5.07 | 1.74 | 1.73 |
Diluted EPS Before Non-Recurring Items | 0.75 | -5.50 | -5.50 | -10.25 | -10.75 |
Diluted Net EPS (GAAP) | 0.75 | -5.50 | 0.25 | -10.25 | -10.75 |